What You'll Want to Know About Acceleron Pharma's Q2 Update
Acceleron Pharma (NASDAQ: XLRN) hasn't generated much excitement for investors so far this year. The stock is down close to 5% year to date while the broader market indexes are up solidly.
The biotech reported its second-quarter financial results after the market closed on Monday. Was there anything for investors to get excited about? Here's what you need to know about the Acceleron's Q2 update.
Image source: Getty Images
Quelle Fool.com
